Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03321526 · ClinicalTrials.gov registry record · Phase 2
A Study to Compare the Efficacy, Safety, and Tolerability of JNJ-42847922 Versus Quetiapine Extended-Release as Adjunctive Therapy to Antidepressants in Adult Participants With Major Depressive Disorder Who Have Responded Inadequately to Antidepressant Therapy
A Phase 2 study, sponsored by Janssen Research & Development.
- Completed
- Registry status
- Phase 2
- Development phase
- 107
- Enrollment target
NCT03321526 is a Phase 2 study that has completed, run by Janssen Research & Development. The registered enrollment target is 107 participants.
The verdict
NCT03321526, a Phase 2 study, has completed, sponsored by Janssen Research & Development.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 107 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the efficacy of flexibly dosed JNJ-42847922 (20 milligram \[mg\] or 40 mg) compared to flexibly dosed quetiapine extended-release (XR) (150 mg or 300 mg) as adjunctive therapy to an antidepressant drug in delaying time to all-cause discontinuation of study drug over a 6-months (24 weeks) treatment period, in participants with major depressive disorder (MDD) who have had an inadequate response to current antidepressant therapy with a selective serotonin reuptake inhibitor (SSRI) or serotonin-norepinephrine reuptake inhibitor (SNRI).
Interventions
- DRUG Quetiapine XR
- DRUG JNJ-42847922
- DRUG Placebo Matching to JNJ-42847922
- DRUG Placebo Matching to Quetiapine XR
- DRUG Selective Serotonin Reuptake Inhibitor (SSRI)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 107 participants |
| Start Date | 2017-12-12 |
| Est. Completion | 2019-06-27 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03321526
The ClinicalTrials.gov registry entry for NCT03321526 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 107 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Quetiapine XR is the first listed.
NCT03321526 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03321526 about?
NCT03321526 is a clinical study titled "A Study to Compare the Efficacy, Safety, and Tolerability of JNJ-42847922 Versus Quetiapine Extended-Release as Adjunctive Therapy to Antidepressants in Adult Participants With Major Depressive Disorder Who Have Responded Inadequately to Antidepressant Therapy". The purpose of this study is to assess the efficacy of flexibly dosed JNJ-42847922 (20 milligram \[mg\] or 40 mg) compared to flexibly dosed quetiapine extended-release (XR) (150 mg or 300 mg) as adjunctive therapy to an antidepressant drug in delaying time to all-cause discontinuation of study drug...
What is the current status of trial NCT03321526?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 107 participants. The study started on 2017-12-12. Estimated completion is 2019-06-27.
What interventions are being tested in trial NCT03321526?
The interventions under investigation include: Quetiapine XR (DRUG), JNJ-42847922 (DRUG), Placebo Matching to JNJ-42847922 (DRUG), Placebo Matching to Quetiapine XR (DRUG), Selective Serotonin Reuptake Inhibitor (SSRI) (DRUG).
Who is sponsoring clinical trial NCT03321526?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.